Prediction of further axillary nodes metastatic load in breast cancer using the Metasin RTqPCR assay for CK19 and Mammaglobin during the intraoperative sentinel node analysis.
Association of Breast Surgery ePoster Library. Udayasankar S. 05/15/17; 166249; P062
Sujatha Udayasankar
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Background: The Metasin assay is currently used in the NHS as an intra-operative test to analyse the sentinel lymph node (SLN) metastasis in breast cancer.
The aim of this study is to evaluate the correlation between cytokeratin (CK19) and mammaglobin (MGB) expression from metastatic axillary SLN using the Metasin assay to the number of additional metastatic nodes found at axillary clearance.
Method: This is a retrospective study, from Oct 2011 – Dec 2014, including all patients positive for metastasis in the sentinel node and then went on to have axillary clearance.
A node is considered positive for macrometastasis if CK19 Cq is less than 25; and MGB < 26. The CK19 and MGB cycle numbers (Cq) were reviewed against the extent of lymph node involvement as assessed following axillary clearance.
Results: During the study, 88 patients' sentinel nodes were found Metasin positive. 37 were CK19 positive, 6 MGB positive and 45 were positive for both. 39 (41.4%) patients were found to have additional nodes positive following axillary clearance.
The median CK19 Cq was 20.8, 18.2 and 17.4 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
The median MGB Cq was 22.35, 21.9 and 19.9 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
Conclusion: With further detailed studies, quantitatively reporting the Metasin results with Cq may help to predict a low likelihood of additional axillary node involvement and thus help avoid unnecessary axillary clearances.
The aim of this study is to evaluate the correlation between cytokeratin (CK19) and mammaglobin (MGB) expression from metastatic axillary SLN using the Metasin assay to the number of additional metastatic nodes found at axillary clearance.
Method: This is a retrospective study, from Oct 2011 – Dec 2014, including all patients positive for metastasis in the sentinel node and then went on to have axillary clearance.
A node is considered positive for macrometastasis if CK19 Cq is less than 25; and MGB < 26. The CK19 and MGB cycle numbers (Cq) were reviewed against the extent of lymph node involvement as assessed following axillary clearance.
Results: During the study, 88 patients' sentinel nodes were found Metasin positive. 37 were CK19 positive, 6 MGB positive and 45 were positive for both. 39 (41.4%) patients were found to have additional nodes positive following axillary clearance.
The median CK19 Cq was 20.8, 18.2 and 17.4 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
The median MGB Cq was 22.35, 21.9 and 19.9 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
Conclusion: With further detailed studies, quantitatively reporting the Metasin results with Cq may help to predict a low likelihood of additional axillary node involvement and thus help avoid unnecessary axillary clearances.
Background: The Metasin assay is currently used in the NHS as an intra-operative test to analyse the sentinel lymph node (SLN) metastasis in breast cancer.
The aim of this study is to evaluate the correlation between cytokeratin (CK19) and mammaglobin (MGB) expression from metastatic axillary SLN using the Metasin assay to the number of additional metastatic nodes found at axillary clearance.
Method: This is a retrospective study, from Oct 2011 – Dec 2014, including all patients positive for metastasis in the sentinel node and then went on to have axillary clearance.
A node is considered positive for macrometastasis if CK19 Cq is less than 25; and MGB < 26. The CK19 and MGB cycle numbers (Cq) were reviewed against the extent of lymph node involvement as assessed following axillary clearance.
Results: During the study, 88 patients' sentinel nodes were found Metasin positive. 37 were CK19 positive, 6 MGB positive and 45 were positive for both. 39 (41.4%) patients were found to have additional nodes positive following axillary clearance.
The median CK19 Cq was 20.8, 18.2 and 17.4 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
The median MGB Cq was 22.35, 21.9 and 19.9 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
Conclusion: With further detailed studies, quantitatively reporting the Metasin results with Cq may help to predict a low likelihood of additional axillary node involvement and thus help avoid unnecessary axillary clearances.
The aim of this study is to evaluate the correlation between cytokeratin (CK19) and mammaglobin (MGB) expression from metastatic axillary SLN using the Metasin assay to the number of additional metastatic nodes found at axillary clearance.
Method: This is a retrospective study, from Oct 2011 – Dec 2014, including all patients positive for metastasis in the sentinel node and then went on to have axillary clearance.
A node is considered positive for macrometastasis if CK19 Cq is less than 25; and MGB < 26. The CK19 and MGB cycle numbers (Cq) were reviewed against the extent of lymph node involvement as assessed following axillary clearance.
Results: During the study, 88 patients' sentinel nodes were found Metasin positive. 37 were CK19 positive, 6 MGB positive and 45 were positive for both. 39 (41.4%) patients were found to have additional nodes positive following axillary clearance.
The median CK19 Cq was 20.8, 18.2 and 17.4 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
The median MGB Cq was 22.35, 21.9 and 19.9 for 1 node positive, 2 nodes positive and >3 nodes positive respectively.
Conclusion: With further detailed studies, quantitatively reporting the Metasin results with Cq may help to predict a low likelihood of additional axillary node involvement and thus help avoid unnecessary axillary clearances.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}